Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Piper Sandler from $15.00 to $23.00. They now have a "neutral" rating on the stock.
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $40.00 to $49.00. They now have a "buy" rating on the stock.
Rigel to Present at the Jefferies London Healthcare Conference
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]